Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06226597

Fitbit Device Use in Overweight Pregnancy

There are set guidelines for weight gain developed by the Institute of Medicine in pregnancy but about three quarters of women gain an inappropriate weight during pregnancy. Many studies have assessed ways to decrease weight gain in these women who gain excess weight, usually through a combination of diet and exercise. Still, often these interventions are difficult to implement, expensive, or have low acceptability. Wearable Fitbit devices have been on the market for years and slowly becoming more inexpensive and easier to use.

Previous studies on non-pregnant women have shown that using the device can help reduce weight gain. In addition, small studies in pregnant women have shown they are accurate for measuring steps and have high acceptability and retention rates. The ability of the Fitbit to assess metrics of sleep including sleep duration and quality will also be assessed.

This project aims to provide overweight and obese pregnant women at the beginning of their pregnancy with the Fitbit device and with regular follow-up to assess if there is effectiveness in increasing the rate of women who meet weight gain guidelines compared to women without the device along with measuring aspects of sleep.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Banner University Medical Center

Tucson, Arizona, 85750, United States

About this study

This is a prospective randomized control trial study. This study aims to assess the relationship between physical activity and sleep metrics in pregnant women as measured using the Fitbit device and the ability to meet Institute of Medicine weight gain guidelines during pregnancy. The hypothesis of the study is that self-realization and monitoring of activity using the Fitbit will encourage the wearer to be increasingly physically active and assist in meeting weight gain guidelines. This study is performed in conjunction with the University of Arizona sensor lab utilizing the MyDataHelps platform which will assist with collection of data from each participant's Fitbit device and subsequent analysis. Mydatahelps is an easily customizable data collection platform that helps researchers collect participant data in a secure HIPAA compliant manner. They are an external company but have no input in the construction of the project This study will have two arms: one with Fitbit wearers and a control arm for routine prenatal care. Compared to control participants who will not have a Fitbit device, we hypothesize that utilization of the Fitbit device will be effective in helping overweight and obese pregnant women meet Institute of Medicine weight gain guidelines.

The primary endpoint is gestational weight gain throughout pregnancy. Weight will be measured pre-pregnancy, at recruitment, 28 weeks, delivery, and 6 weeks postpartum.

Secondary endpoints will also be measured and include:

  • Acceptability of device and loss to follow-up
  • Obstetrical outcomes include rate of developing gestational diabetes, gestational hypertension and preeclampsia, preterm delivery, cesarean delivery rate, intrauterine growth restriction, and macrosomia
  • Neonatal outcomes, including birth weight and admission to NICU
  • Fitbit outcome data, including steps taken, calories burned, sleep duration and Fitbit derived sleep quality
  • Questionnaire data: Global Physical Activity Questionnaire (GPAQ), Cambridge Worry Scale and Pittsburgh Sleep Quality Index at baseline, 28 weeks and delivery

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • At least 18 years old
  • Currently pregnant with a singleton pregnancy
  • Pre-pregnancy body mass index over 25
  • Owns and uses a smartphone
  • Agreeable to participate in the study by wearing a fitbit device consistently (day and night) for the duration of pregnancy

Exclusion criteria

  • Multiple gestations
  • Beyond the first trimester at time of initial enrollment
  • Known maternal cardiac disease
  • Pre-gestational diabetes
  • High risk of preterm labor
  • Any contraindications to exercise
  • Unwilling to wear device consistently or share tracked data

Treatment and study plan

Fitbit device

Device

Daily use of a fitbit wearable activity tracker device.

Primary outcomes

  1. Gestational weight gain during pregnancy

    Time frame: From pre-pregnancy or initial prenatal visit until 6 weeks postpartum

    Weight will be measured pre-pregnancy, at recruitment (ideally initial prenatal visit), 28 weeks gestation, at delivery and 6 weeks postpartum

Secondary outcomes

  1. Number of patients reporting adverse events related to device

    Time frame: Through duration of participation, average of 8-9 months

    Tolerability of wearing the device consistently, any adverse effects

  2. Number of patients lost to follow-up

    Time frame: 18 months

    Individuals that discontinue follow-up or study inclusion

  3. Incidence of intrauterine growth restriction

    Time frame: At delivery

    Number of pregnancies affected by intrauterine growth restriction

  4. Incidence of fetal macrosomia

    Time frame: At delivery

    Number of pregnancies affected by fetal macrosomia

  5. Incidence of gestational hypertension

    Time frame: At delivery

    Number of patients who develop gestational hypertension in pregnancy

  6. Incidence of gestational diabetes

    Time frame: At delivery

    Number of patients who develop gestational diabetes in pregnancy

  7. Incidence of preeclampsia

    Time frame: At delivery

    Number of patients who develop preeclampsia in pregnancy

  8. Incidence of preterm delivery

    Time frame: At delivery

    Number of patients who experience preterm delivery

  9. Incidence of cesarean delivery

    Time frame: At delivery

    Number of patients who have cesarean delivery

  10. Neonatal birth weight

    Time frame: At delivery

    Neonatal birth weight in grams

  11. Incidence of NICU admission

    Time frame: At delivery

    Number of fetuses requiring admission to neonatal ICU care

  12. Average number of daily steps taken per individual

    Time frame: At delivery

    Average number of daily steps taken per individual as recorded by fitbit device

  13. Calories burned per individual

    Time frame: At delivery

    Daily calories burned per individual, as measured by fitbit device, in kcal

  14. Daily sleep duration

    Time frame: At delivery

    Daily and average sleep duration in hours per individual, as measured by fitbit device

  15. Fitbit derived sleep quality

    Time frame: At delivery

    Fitbit device determined nightly sleep score

  16. Global Physical Activity Questionnaire (GPAQ) score

    Time frame: At initial enrollment, 28 weeks gestation and delivery

    Questionnaire data

  17. Cambridge Worry Scale score

    Time frame: At initial enrollment, 28 weeks gestation and delivery

    Questionnaire data

  18. Pittsburg Sleep Quality Index score

    Time frame: At initial enrollment, 28 weeks gestation and delivery

    Questionnaire data

Sponsors and collaborators

Lead sponsor

University of Arizona

Other

Registry information

Official study title

Fitbit Device Use in Overweight Pregnant Women to Improve Adherence to Gestational Weight Gain Guidelines

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Jan 26, 2024
Registry last updated
May 7, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.